公开(公告)号：US12078638B2

公开(公告)日：2024-09-03

申请号：US17835418

申请日：2022-06-08

Applicant: Genentech, Inc.

Inventor： Priti Hegde ,  Mahrukh Huseni

IPC: C12Q1/6886 ,  A61K31/404 ,  A61K39/395 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

CPC classification number: G01N33/5748 ,  A61K31/404 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/2827 ,  C12Q1/6886 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

公开(公告)号：US10767232B2

公开(公告)日：2020-09-08

申请号：US15836729

申请日：2017-12-08

Applicant: Genentech, Inc.

Inventor： Mahrukh Huseni

IPC: C12Q1/6886 ,  G01N33/574 ,  C07K16/28

Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.

公开(公告)号：US20240410013A1

公开(公告)日：2024-12-12

申请号：US18653413

申请日：2024-05-02

Applicant: Genentech, Inc.

Inventor： Habib HAMIDI ,  Mahrukh Huseni ,  Romain Francois Banchereau

IPC: C12Q1/6886 ,  A61K39/00 ,  A61K39/395

Abstract: The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.

公开(公告)号：US20230049152A1

公开(公告)日：2023-02-16

申请号：US17864074

申请日：2022-07-13

Applicant: GENENTECH, INC.

Inventor： Gautham Gampa ,  Iraj Hosseini ,  Mahrukh Huseni ,  James T. Koerber ,  Jian Mehr-Dean Payandeh ,  Sascha Rutz ,  Yonglian Sun ,  Cecilia P. C. Chiu ,  Teresita A. Delfino

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.

公开(公告)号：US12240910B2

公开(公告)日：2025-03-04

申请号：US17864074

申请日：2022-07-13

Applicant: GENENTECH, INC.

Inventor： Gautham Gampa ,  Iraj Hosseini ,  Mahrukh Huseni ,  James Thomas Koerber ,  Jian Mehr-Dean Payandeh ,  Sascha Rutz ,  Yonglian Sun ,  Cecilia P. C. Chiu ,  Teresita Arenzana Delfino

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.

公开(公告)号：US20210332143A1

公开(公告)日：2021-10-28

申请号：US17249530

申请日：2021-03-04

Applicant: Genentech, Inc.

Inventor： Mahrukh Huseni ,  Joanna E. Klementowicz ,  Yijin Li ,  Li-Fen Liu ,  Sanjeev Mariathasan ,  Mark Merchant ,  Luciana Molinero ,  Lifen Wang ,  Nathaniel West ,  Patrick Williams ,  Chi Yung Yuen ,  Edward Namserk Cha ,  Yulei Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/337 ,  A61K47/64

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.